ALF 2019 Preliminary program

08:00-08:30 OPENING CEREMONY

08:30-10:00 SECTION I: Viral hepatitis

Chairs: MacDonald D, Ostojic R, Tomasiewicz K

  • Effectiveness of DAA therapy: Real life data from Central Europe (Flisiak R, PL) 
  • On the road to eradicate hepatitis C: Croatian national strategy (Vince A, HR) 
  • Post SVR follow-up in chronic HCV: When is it necessary? (MacDonald D, UK)
  • Hepatitis B: should we stop NUCs and when? (Husic Selimovic A, BH) 
  • HBV reactivation in the immunocompromised patient (Milovanovic T, SRB)

10:30-12:00 SECTION II: Role of microbes in noninfective liver conditions

Chairs: Jarcuska P, Ladic D, Kardum D

  • Type and prognostic impact of infectious agents in patients with cirrhosis (Grgurević I, HR)
  • Infections in severe alcoholic hepatitis (Pavlov C, RUS)
  • The role of gut microbiota in the progression of NAFLD to HCC (Kukla M, PL)
  • Predictive value of gut dysbiosis on ACLF mortality: the role of probiotics? (Milić S, HR)
  • Liver in sepsis (Salkic N, BH)

12:15-13:00 LUNCH SESSION: Ultrasound for hepatologists

Introductory lecture: US in liver cirrhosis: diagnosis and follow-up (Manolev A, MK)

Hand-on session:  Bende F, Lalovac M, Matic V, Toga T, Mustapic S, Stojsavljevic S

13:00-14:00 LUNCH

14:00-15:30 SECTION III: Infections in patients with liver cirrhosis

Chairs: Hunyady B, Krznaric Z, Pinzani M

  • Hepatology: predictions for the future (Pinzani M, UK)
  • Bacterial Infections Change Natural History of Cirrhosis Irrespective of Liver Disease Severity (Tsochatzis E, UK)
  • SBP: a diagnostic algorithm for clinicians and future perspectives (O'Brien A, UK)
  • Early predictors of bacterial infection in cirrhosis: CRP and other biomarkers (Papp M, HU)
  • Proton pump inhibitors and the risk of bacterial infections in cirrhosis (Puljiz Z, HR)

16:00-17:30 SECTION IV: Infections in the transplantation setting

Chairs: Hrstic I, Skladany L, Turcic P

  • Early infections after liver transplantation (Majerovic M, HR)
  • The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection in liver transplant recipients (Filipec Kanizaj T, HR)
  • ACLF due to bacterial infection -indications and timing for liver transplantation? (Virovic Jukic L, HR)
  • Prophylaxis against CMV infection in the transplanted patients? (Sperl J, CZ)

17:30-18:00 CONCLUDING REMARKS